Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
R&D to Revenue
121.80%
Fiscal year · Period ending:
LCTX R&D to Revenue
Latest reported121.80%period ending
Latest reported121.80%period ending
LCTX FY R&D/Revenue (0.00% → 121.80%)
Latest values, visible window
High-resolution chart · PNG
LCTX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 121.7986% | |
| 131.298% | |
| 175.5729% | |
| 95.1302% | |
| 870.4825% | |
| 1,593.4023% | |
| 1,214.3437% | |
| 1,479.8729% | |
| 1,340.625% | |
| 1,603.286% | |
| 1,681.2944% | |
| 1,928.3376% | |
| 930.0719% | |
| 1,070.1766% | |
| 314.591% | |
| 214.4397% | |
| 154.2196% | |
| 113.4608% | |
| 92.5193% | |
| 122.3958% | |
| 168.9201% | |
| 163.1753% | |
| 162.2901% | |
| 285.1248% | |
| 1,109.2689% | |
| 6,406.3876% | |
| 472.3394% | |
| 566.6667% | |
| 2,100% | |
| 0% | |
| 1,800% | |
| 800% | |
| 0% | |
| 0% |